Sara Radcliffe

President & CEO, California Life Sciences Association (CLSA)


Health IT Hubs: State-of-the-State

Looking forward, the answers to tough questions facing regional markets will define the future and success of healthcare nationally. How can organizations manage cost by rendering healthcare less labor intensive while at the same time offering customization on a mass scale? How can we shift the balance of power to the patient in the evolving care model? Can patients ever truly be in control of their health if all of their most basic data isn’t accurate, available in one place and readily accessible? What political and ethical changes must occur to support these shifts?

Regions around the country are answering these questions differently. The Twin Cities, San Francisco, Boston and Nashville are hubs where trends are being carefully observed and expanded upon. Hear from chief executives of state-based industry associations who will provide a high-level SWOT analysis of their regions. Learn about the nuances in each state and how we can better deliver on the triple aim of lower cost, improved quality and better health by working together. Q&A to follow.

What you’ll learn:

  • How health IT priorities vary state-by-state and what we can do to connect the dots to transform national outcomes
  • Common challenges and opportunities based on healthcare sectors more prominently represented in each state
  • How to connect these regions to facilitate business development and improve healthcare outcomes statewide and globally
  • Areas of predicted entrepreneurial growth by region


Sara Radcliffe was appointed the president and Chief Executive Officer of the California Life Sciences Association (CLSA) in December 2014. She formerly served as the Executive Vice President for Health at the Biotechnology Industry Organization (BIO). Previously, Sara served as Senior Director, Biologics & Biotechnology at the Pharmaceutical Research and Manufacturers of America (PhRMA). She also served in the Alliance and Technology Group at SmithKline Beecham Pharmaceuticals as a Research and Development Policy Analyst, working on evaluation and communication of the promise, ethics, and impact of rapidly-developing technologies in DNA Research. In addition she worked for the Core Services Committee of the New Zealand Ministry of Health. Sara holds a Master of Public Health and a Master of Arts in Philosophy from the Johns Hopkins University, and a Bachelor of Arts from Wellesley College.